Tevogen Bio Holdings Inc.
TVGN
$0.9364
$0.0323.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.66% | -17.73% | 574.26% | 133.81% | 288.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.68% | -64.91% | 365.99% | 161.74% | 293.64% |
| Operating Income | 36.68% | 64.91% | -365.99% | -161.74% | -293.64% |
| Income Before Tax | 43.04% | -192.03% | -160.02% | -50.68% | 56.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.04% | -192.03% | -160.02% | -50.68% | 56.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.04% | -192.03% | -160.02% | -50.68% | 56.44% |
| EBIT | 36.68% | 64.91% | -365.99% | -161.74% | -293.64% |
| EBITDA | 37.45% | 65.00% | -374.39% | -164.52% | -299.05% |
| EPS Basic | 22.34% | -185.10% | 39.88% | -6.77% | 78.69% |
| Normalized Basic EPS | 52.30% | 70.34% | 5.95% | -57.66% | -203.88% |
| EPS Diluted | 23.50% | 73.10% | 39.88% | -6.77% | 78.37% |
| Normalized Diluted EPS | 52.30% | 69.25% | 5.95% | -57.66% | -203.88% |
| Average Basic Shares Outstanding | 19.55% | 17.53% | 331.03% | 41.81% | 28.47% |
| Average Diluted Shares Outstanding | 19.55% | 13.36% | 331.03% | 41.81% | 28.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |